Drug Trial Radar · NCT06565611
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Aug 5, 2024
Primary completion
Feb 5, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Palatin Technologies, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
Conditions
- Obesity
Interventions
bremelanotideDrug
bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
tirzepatideDrug
tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight between treatment armsTime frame: Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University Clinical Research-DeLand LLC, d/b/a Accel Research
DeLand, Florida
Lynn Health Science Institute
Oklahoma City, Oklahoma
Coastal Carolina Research Center
North Charleston, South Carolina
Lynn Institute of Chattanooga
Chattanooga, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.